이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

장기 인공호흡이 ALS 환자와 그 가족의 삶의 질에 미치는 영향 (ALS-LTMV)

2026년 9월 16일 업데이트: Haukeland University Hospital

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is two to three years. The patient physical and psychological sufferings in ALS are immense, and apart from Riluzole, there is no effective treatment. Care of advanced ALS have an estimated cost of 4-8 million NOK per year. Perhaps the most challenging topic of ALS care is the decision to extend ventilation support into the stages of disease that require treatment both during day and night. In these cases, treatment is clearly life-sustaining and although quality of life may be maintained, the burden of caregiving imposed upon family or health care workers is huge, regardless of tracheostomy (TIV) or non-invasive (NIV) modality.

The present study is a longitudinal questionnaire study in Norway measuring overall quality of life, health-related quality of life, and disease-specific quality of life in ALS patients, partners and children before and after the introduction of life sustaining ventilation support. The investigators aim to increase the knowledge on how life-sustaining ventilation support with NIV or TIV affects the quality of life in ALS patients, life partners and children. The results from the study may provide crucial information for clinicians and patients on one of the most difficult ethical issues of ALS treatment. The investigators anticipate that this information will facilitate a shared decision making processes, weighing benefits and disadvantages in a wider perspective.

연구 개요

연구 유형

중재적

등록 (추정된)

200

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

      • Bergen, 노르웨이
      • Lørenskog, 노르웨이
        • 모병
        • Akershus University Hospital
        • 수석 연구원:
          • Ola Nakken
        • 연락하다:
          • Ola Nakken
      • Oslo, 노르웨이
        • 모병
        • Oslo University Hospital
        • 수석 연구원:
          • Angelina Maniaol
        • 연락하다:
          • Angelina Maniaol
      • Sarpsborg, 노르웨이, 1714
        • 아직 모집하지 않음
        • Østfold Hospital Kalnes
        • 연락하다:
      • Stavanger, 노르웨이
        • 모병
        • Stavanger University Hospital
        • 수석 연구원:
          • Katrin Ruth Schlüter
        • 연락하다:
          • Katrin Ruth Schlüter
      • Tromsø, 노르웨이
        • 모병
        • Universitetssykehuset Nord-Norge
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Agnethe Eltoft, MD
        • 수석 연구원:
          • Monica Vold, MD
      • Trondheim, 노르웨이
        • 모병
        • St. Olavs Hospital
        • 연락하다:
          • Eivind Brønstad, MD PhD
        • 수석 연구원:
          • Eivind Brønstad, MD PhD
    • Nordland
    • Vest Agder
      • Kristiansand, Vest Agder, 노르웨이
        • 모병
        • Sørlandet Hospital Trust
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

8년 이상 (어린이, 성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion criteria for patients:

  1. A clinical diagnosis of probable ALS according to the revised El Escorial criteria
  2. Progression of the illness leading the consulting physician to offer treatment with LTMV
  3. Can communicate in Norwegian

Inclusion criteria for partners of ALS patients:

  1. Partner of a patient with ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
  2. Can communicate in Norwegian

Inclusion criteria for children:

  1. Children from 8 years and older having a parent who suffers from ALS with progression of the illness leading the consulting physician to offer treatment with LTMV
  2. Can communicate in Norwegian

Exclusion criteria for patients, partners and children of ALS patients:

1. Potential participants with cognitive impairment or dementia.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: LTMV 연명치료를 선택한 ALS 환자와 그 가족

Patients that choose life prolonging treatment with long term mechanical ventilation support

활성 비교기: LTMV의 연명치료를 거부하는 ALS 환자와 그 가족

Patients that decline life prolonging treatment with long term mechanical ventilation support

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall quality of life assessed by the "Quality of Life Scale"
기간: At inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

At inclusion
Overall quality of life assessed by the "Quality of Life Scale"
기간: 3 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

3 months after inclusion
Overall quality of life assessed by the "Quality of Life Scale"
기간: 9 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

9 months after inclusion
Overall quality of life assessed by the "Quality of Life Scale"
기간: 15 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

15 months after inclusion
Overall quality of life assessed by the "Quality of Life Scale"
기간: 21 months after inclusion

"Quality of Life Scale" total score (range 16-112). Higher score indicates better quality of life.

21 months after inclusion

2차 결과 측정

결과 측정
측정값 설명
기간
Health-related quality of life assessed by the "EQ-5D-5L"
기간: At inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

At inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 3 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

3 months after inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 9 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

9 months after inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 15 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

15 months after inclusion
Health-related quality of life assessed by the "EQ-5D-5L"
기간: 21 months after inclusion

"EQ-5D-5L" index score and EQ-VAS score (range 0-100) where higher scores indicates better health-related quality of life.

21 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: At inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

At inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 3 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

3 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 9 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

9 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 15 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

15 months after inclusion
Disease-specific quality of life assessed by "Amyotrophic lateral sclerosis assessment scale - 5 items (ALSAQ-5)"
기간: 21 months after inclusion

"ALSAQ-5" score (range 0-100), with 0 reflecting the best health state

21 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: At inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

At inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 3 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

3 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 9 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

9 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 15 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

15 months after inclusion
Health-related quality of life assessed by "Severe Respiratory Insufficiency Questionnaire"
기간: 21 months after inclusion

"Severe Respiratory Insufficiency Questionnaire" score (range 0-100), with 100 reflecting the best health state.

21 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
기간: At inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

At inclusion
Health-related quality of life assessed by "Kidsscreen-27"
기간: 3 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

3 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
기간: 9 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

9 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
기간: 15 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

15 months after inclusion
Health-related quality of life assessed by "Kidsscreen-27"
기간: 21 months after inclusion

"Kidsscreen-27" score where mean (±SD) scores of 50 ± 10 define normality for children and adolescents aged 8-18 years across Europe. Higher scores indicate a better health-related quality of life.

21 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
기간: At inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

At inclusion
Caregiver burden assessed by "Zarit Burden Interview"
기간: 3 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

3 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
기간: 9 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

9 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
기간: 15 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

15 months after inclusion
Caregiver burden assessed by "Zarit Burden Interview"
기간: 21 months after inclusion

"Zarit Burden Interview" total score (range 0-88 where a higher score indicates greater burden).

21 months after inclusion

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2023년 4월 21일

기본 완료 (추정된)

2032년 8월 21일

연구 완료 (추정된)

2032년 8월 21일

연구 등록 날짜

최초 제출

2023년 1월 30일

QC 기준을 충족하는 최초 제출

2023년 2월 21일

처음 게시됨 (실제)

2023년 2월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 21일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 16일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다